drugset / Trial / NCT00873197

PK, Tolerability and Safety of the Co-administration of Sancuso® (Transdermal Granisetron) and IV Granisetron

NCT00873197

Phase 1 Completed 12 enrolled Kyowa Kirin, Inc.
NaSingle-groupOpen-labelOther

Summary

This study has been designed to investigate the pharmacokinetic and safety profile of the co-administration of intravenous (IV) and transdermal granisetron, as well as characterise the pharmacokinetics of multiple transdermal dosing.

Timeline

Start
2009-04
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Granisetron Other / unclassified 0.01 mg/kg Intravenous
Subject Granisetron Other / unclassified 3.1 mg Intravenous

Indications

No indication recorded.